A Phase III Study of Selumetinib NSC 748727, IND 77782 or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas LGGs Lacking BRAFV600E or IDH1 Mutations

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04576117

Study #:
CMH - ACNS1931

Start Date:
Jul 20, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04576117

View Complete Trial Details & Eligibility at ClinicalTrials.gov